The European Commission (EC) approves Kymriah, the first-ever U.S. FDA approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers.

A leading pediatric oncologist at CHOP, Dr. Grupp is now Chief of the Section of Cellular Therapy and Transplant in the Hospital’s Division of Oncology.

Updated results from a global clinical trial of the CAR T-cell therapy for ALL reveal that children and young adults continued to show high rates of durable, complete remission of their disease.

The FDA approval of Kymriah™ has shifted the paradigm for pediatric cancer treatment — and at Children's Hospital of Philadelphia, more cell therapies are on the horizon.

This is a game changer for the treatment of pediatric patients battling leukemia and a pivotal milestone in this new era of cellular therapies that treat cancer with a patient’s own immune system.

Five years after her T-cell therapy for ALL, Emily remains cancer-free. CHOP has since treated more than 170 patients in clinical trials that have seen a 93% remission rate.

The experimental, personalized cell therapy that amps up the patient's own immune system has passed a critical milestone in the path to full FDA approval.

After four years of battling leukemia, Mitch was no longer responding to his cancer therapy. But new immunotherapy options at Children's Hospital gave him another chance to be a kid.

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study.

Ninety percent of children and adults with acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy, CTL019.